SCHEMBL7723822

SCHEMBL7723822

Cc1cc(O)cc(Cl)c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.59
CHRM1 P11229 1/20 0.59
ALOX15 P16050 1/20 0.59
MAOA P21397 1/20 0.59
TBXA2R P21731 1/20 0.59
ADRA1A P35348 1/20 0.59
HTR2B P41595 1/20 0.59
HSD17B10 Q99714 2/20 0.50
HPGD P15428 1/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
ESR2 Q92731 3/20 0.42
ESR1 P03372 2/20 0.42
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ACHE P22303 2/20 0.37
HSP90AA1 P07900 1/20 0.37
ATM Q13315 1/20 0.37
GAA P10253 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL83132 0.86 CYP3A4 (0.58) CYP3A4CHRM1ALOX15MAOATBXA2R
Ammonia Solution, Strong SCHEMBL10706299 0.83 CYP3A4 (0.55) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL253926 0.80 CYP3A4 (0.58) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL3788864 0.79 CYP3A4 (0.59) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL7786855 0.79 CYP3A4 (0.50) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL6800963 0.79 CYP3A4 (0.75) CYP3A4CHRM1ALOX15MAOATBXA2R
Methane SCHEMBL27301821 0.77 CYP3A4 (0.55) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL3785424 0.75 CYP3A4 (0.54) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL22265086 0.75 CYP3A4 (0.46) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL5249009 0.75 CYP3A4 (0.54) CYP3A4CHRM1ALOX15MAOATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103156800-A Antibacterial and washing-free hand-cleaning liquid ZHANG GUIPING 2013-06-19 CN claimed
WO-2022083569-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-04-28 WO disclosed
CN-103156800-A Antibacterial and washing-free hand-cleaning liquid ZHANG GUIPING 2013-06-19 CN disclosed
US-8338412-B2 Inhibitors of P38 VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-25 US disclosed
US-20110281878-A1 INHIBITORS OF p38 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 US disclosed
US-20110160163-A1 INHIBITORS OF p38 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-30 US disclosed
WO-2011056589-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT COMPANY, LLC (US) 2011-05-12 WO disclosed
US-7919513-B2 Inhibitors of p38 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-05 US disclosed
US-6337375-B1 RESIN WITH COLOR AND FLUORESCING AGENT INTERNATIONAL BUSINESS MACHINES CORPORATION 2002-01-08 US disclosed
EP-1145083-A2 HYBRID SURFACE MODIFICATION PROCESS AND ARTICLE BMC Industries, Inc. (US) 2001-10-17 EP disclosed
US-4410738-A Preparation of meta-chlorophenols by selective hydrodechlorination of polychlorophenols RHONE-POULENC INDUSTRIES (FR) 1983-10-18 US disclosed
US-4390675-A EPOXYFULVENE, ACID CATALYST ASHLAND OIL, INC. (US) 1983-06-28 US disclosed
EP-0037353-B1 PROCESS FOR THE ETHERIFICATION OF PHENOLS RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1983-06-08 EP disclosed
EP-0076221-A1 Process for the etherification of phenols RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1983-04-06 EP disclosed
EP-0053280-A1 Sealing composition, method for preparing said composition, integrated circuit module sealed therewith, and process for sealing International Business Machines Corporation (US) 1982-06-09 EP disclosed
EP-0009190-B1 CURABLE COMPOSITION USEFUL FOR SCREEN-PRINTING, A CURED COATING COMPRISING SAID COMPOSITION AND PROCESS FOR SOLDERING PRINTED CIRCUIT BOARDS USING SAID COMPOSITION International Business Machines Corporation (US) 1982-04-28 EP disclosed
EP-0046719-A1 Process for the etherification of phenols RHONE-POULENC INDUSTRIES (FR) 1982-03-03 EP disclosed
EP-0037353-A1 Process for the etherification of phenols RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1981-10-07 EP disclosed
US-4292230-A Screen-printing composition and use thereof INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 1981-09-29 US disclosed
EP-0009190-A1 Curable composition useful for screen-printing, a cured coating comprising said composition and process for soldering printed circuit boards using said composition International Business Machines Corporation (US) 1980-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160163-A1 INHIBITORS OF p38 ZAP70, MAPK1, MAP3K20 CYP3A4 4862/4885CHRM1 4627/4885ALOX15 2796/4885
US-20110281878-A1 INHIBITORS OF p38 MAPK1, MAPK3, MAP3K1 CYP3A4 4859/4885CHRM1 4684/4885ALOX15 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.